CYFRA 21-1 and NSE: additional markers in lung cancer

CYFRA 21-1 and neuron-specific enolase (NSE) are tumor-associated blood markers. They may provide additional information in selected clinical situations but are not intended for lung cancer screening or independent diagnosis. A normal result does not exclude a tumor, and elevation also occurs in noncancerous disease.

CYFRA 21-1: a cytokeratin 19 fragment

Cytokeratins form elements of the internal framework of epithelial cells. Protein breakdown can release soluble cytokeratin 19 fragments into the bloodstream; CYFRA 21-1 assays quantify these fragments. Their concentration depends on cellular turnover, tissue injury and clearance, rather than tumor presence alone.

Raised CYFRA 21-1 is more often associated with non-small cell lung cancer (NSCLC), particularly squamous cell carcinoma, but it is neither lung-specific nor specific to one histological type. It does not replace biopsy or reliably distinguish NSCLC from small cell cancer.

If elevated before treatment, its trend may sometimes help follow established disease. A decline after surgery or systemic treatment may reflect reduced tumor burden. Persistent elevation or a rise requires assessment of possible causes alongside symptoms and imaging, rather than an automatic conclusion of residual tumor or recurrence. Fixed decline times and promises of detecting recurrence a year early are not universal rules.

NSE: neuron-specific enolase

NSE is a form of the enzyme enolase associated mainly with neurons and neuroendocrine cells. It can rise in small cell lung cancer (SCLC), neuroblastoma and some other tumors. It is not specific to a single tumor and is not always elevated in SCLC.

In established SCLC, serial NSE measurements may supplement assessment of treatment response and progression. Temporary changes may occur after treatment begins because of cell breakdown. However, an isolated rise, failure to normalize or a particular change interval cannot independently establish chemotherapy failure or recurrence. NSE alone is insufficient for comprehensive treatment monitoring.

Limitations and specimen quality

Reference intervals, units and acceptable specimens depend on the method. Use the laboratory report’s values and compare results from comparable methods. The previously cited “normal CYFRA 21-1 ≤0.7 ng/l” combined a questionable value and unit and has been removed; no universal CYFRA 21-1 or NSE cutoff is set here.

CYFRA 21-1 and NSE may increase with impaired kidney or liver function and certain benign lung diseases. Hemolysis is particularly important for NSE: red blood cells and platelets contain the enzyme, so cell damage or delayed specimen processing can falsely increase the result. Whether serum or plasma is acceptable depends on the instructions; some NSE systems require serum only.

Role in assessment

Lung cancer diagnosis relies on clinical evaluation, imaging and, whenever possible, morphological examination. Combined CYFRA 21-1 and NSE measurement does not replace histological classification. If biopsy is unavailable or unsafe, a specialist team determines management; tumor markers can form only part of the overall evidence.

At DIAGEN PLUS, CYFRA 21-1 and NSE are regarded as additional investigations requested by a clinician. Their need, repetition schedule and influence on treatment are individualized alongside clinical findings and the oncology follow-up plan.